We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $697M
1-Year Est. Return 79.73%
This Fund
S&P 500
This Quarter Est. Return
+1.53%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$505M
AUM Growth
+$162M
Cap. Flow
+$166M
Cap. Flow %
32.79%
Top 10 Hldgs %
36.69%
Holding
110
New
32
Increased
27
Reduced
17
Closed
21

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$19.7M
2
JNJ icon
Johnson & Johnson
JNJ
+$16.9M
3
AMN icon
AMN Healthcare
AMN
+$14.3M
4
CI icon
Cigna
CI
+$14.3M
5
ALBO
Albireo Pharma Inc
ALBO
+$13.9M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$8.84M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$8.57M
3
RCM
R1 RCM Inc. Common Stock
RCM
+$8.51M
4
LLY icon
Eli Lilly
LLY
+$7.54M
5
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
+$6.16M

Sector Composition

Rank Sector Weight
1 Healthcare 74.38%
2 Consumer Staples 0.82%
3 Financials 0.57%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GYRE icon
76
Gyre Therapeutics
GYRE
$709M
$854K 0.17%
26,495
– –
ZSAN
77
DELISTED
Zosano Pharma Corporation
ZSAN
$733K 0.15%
+12,930
New +$602K
NBP
78
NovaBridge Biosciences American Depositary Shares
NBP
$202M
$705K 0.14%
15,000
-103,409
-87% -$3.41M
IDYA icon
79
IDEAYA Biosciences
IDYA
$3.5B
$691K 0.14%
55,000
– –
DFHTU
80
DELISTED
Deerfield Healthcare Technology Acquisitions Corp. Unit
DFHTU
$532K 0.11%
+50,000
New +$527K
NGNE icon
81
Neurogene
NGNE
$694M
$460K 0.09%
1,916
– –
RAPT
82
DELISTED
RAPT Therapeutics
RAPT
$460K 0.09%
1,787
– –
CASI
83
DELISTED
CASI Pharmaceuticals
CASI
$344K 0.07%
+22,500
New +$424K
PANA.U
84
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
$180K 0.04%
+15,000
New +$173K
BNGO icon
85
Bionano Genomics
BNGO
$12.7M
$174K 0.03%
447
-2,130
-83% -$826K
MYOV
86
DELISTED
Myovant Sciences Ltd.
MYOV
$142K 0.03%
+10,100
New +$188K
SNDX icon
87
Syndax Pharmaceuticals
SNDX
$1.78B
$71K 0.01%
+4,796
New +$73.1K
GDRX icon
88
GoodRx Holdings
GDRX
$1.27B
$56K 0.01%
+1,000
New +$52.9K
PMVP icon
89
PMV Pharmaceuticals
PMVP
$62.9M
$36K 0.01%
+1,000
New +$36.8K
BIIB icon
90
Biogen
BIIB
$30.3B
– –
-13,800
Closed -$3.69M
BIIB icon
91
PUT
Biogen
BIIB
$30.3B
– –
-13,800
Closed -$3.69M
BSX icon
92
Boston Scientific
BSX
$72.1B
– –
-112,036
Closed -$3.93M
IMVT icon
93
Immunovant
IMVT
$8.13B
– –
-152,450
Closed -$3.71M
INGN icon
94
Inogen
INGN
$164M
– –
-54,000
Closed -$1.92M
LLY icon
95
Eli Lilly
LLY
$1.05T
– –
-45,901
Closed -$7.54M
MRK icon
96
Merck
MRK
$316B
– –
-119,839
Closed -$8.84M
NERV icon
97
PUT
Minerva Neurosciences
NERV
$209M
– –
-30,413
Closed -$878K
OSUR icon
98
OraSure Technologies
OSUR
$277M
– –
-460,000
Closed -$5.35M
PGNY icon
99
Progyny
PGNY
$2.29B
– –
-39,310
Closed -$1.01M
STRO icon
100
Sutro Biopharma
STRO
$411M
– –
-14,840
Closed -$1.15M
1 2 3
4
5

Similar funds

GUB
Golden Unicorn BVI Road Town $697M AUM 55.92% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $696M AUM 17.86% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return
TCM
Tensile Capital Management Larkspur, California $698M AUM 2.4% 1-Year Est. Return
CA
Calton & Associates Tampa, Florida $696M AUM 18.3% 1-Year Est. Return
SAM
Silverback Asset Management Chapel Hill, North Carolina $699M AUM 72.42% 1-Year Est. Return
ACM
Academy Capital Management Waco, Texas $699M AUM 12.08% 1-Year Est. Return

Sio Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Sio Capital Management held 110 positions worth $505M, up 47% from $343M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Sio Capital Management deployed $166M of net new capital in Q3 2020, opening 32 new positions and adding to 27 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 194,744 shares worth $14.8M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 76% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was GW Pharmaceuticals Plc American Depositary Shares, an estimated $8.57M trimmed.

  • Sio Capital Management's largest Q3 2020 buy was BioMarin Pharmaceuticals: 194,744 shares worth $14.8M.
  • Sio Capital Management added most to HILL-ROM HOLDINGS, INC. in Q3 2020, an estimated $10.8M increase.
  • Sio Capital Management's biggest Q3 2020 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $8.57M.
  • Sio Capital Management fully exited Merck in Q3 2020, selling an estimated $8.84M.
  • Sio Capital Management's ten largest holdings make up 37% of its $505M portfolio in Q3 2020.
  • Sio Capital Management opened 32 new positions and closed 21 in Q3 2020.
  • Sio Capital Management's portfolio value rose 47% quarter-over-quarter to $505M.

Based on Sio Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.